CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.08.23	Cellectis Provides Full Report for Second Quarter 2023 Financial Results (GlobeNewswire)
01.08.23	Monthly information on share capital and company voting rights (GlobeNewswire)
27.07.23	Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
12.07.23	Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors (GlobeNewswire)
05.07.23	Monthly information on share capital and company voting rights (GlobeNewswire)
28.06.23	Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023 (GlobeNewswire)
13.06.23	Monthly information on share capital and company voting rights (GlobeNewswire)
09.06.23	Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
05.06.23	Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event (GlobeNewswire)
31.05.23	Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies (GlobeNewswire)
17.05.23	Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 (GlobeNewswire)
12.05.23	Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors (GlobeNewswire)
11.05.23	Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
10.05.23	Monthly information on share capital and company voting rights (GlobeNewswire)
04.05.23	Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 (GlobeNewswire)
02.05.23	Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annua (GlobeNewswire)
27.04.23	Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
24.04.23	Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab (GlobeNewswire)
17.04.23	Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeti (GlobeNewswire)
12.04.23	Monthly information on share capital and company voting rights (GlobeNewswire)
11.04.23	Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 (GlobeNewswire)
04.04.23	Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million (GlobeNewswire)
15.03.23	Monthly information on share capital and company voting rights (GlobeNewswire)
14.03.23	Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire)
06.03.23	Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
01.03.23	Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 (GlobeNewswire)
09.02.23	Monthly information on share capital and company voting rights (GlobeNewswire)
10.03.20	US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis (Businesswire)
04.03.20	Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results (Businesswire)
04.03.20	Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products (Businesswire)
25.02.20	Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST (Businesswire)
18.02.20	Cellectis and Servier Expand Collaboration on UCART19 Products (Businesswire)
15.01.20	First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia (Businesswire)
06.01.20	Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery (Businesswire)
02.12.19	1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (Businesswire)
20.11.19	Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells (Businesswire)
13.11.19	Cellectis Publishes Creation of "Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications (Businesswire)
06.11.19	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019 (Businesswire)
31.10.19	Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST (Businesswire)
29.10.19	First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma (Businesswire)
01.10.19	Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates (Businesswire)
06.08.19	Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 (Businesswire)
08.07.19	Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way (Businesswire)
26.06.19	Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 (Businesswire)
07.05.19	Cellectis Reports Financial Results for First Quarter 2019 (Businesswire)
02.04.19	FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients (Businesswire)
11.03.19	Cellectis Reports 4th Quarter and Full Year 2018 Financial Results (Businesswire)
07.03.19	Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio (Businesswire)
25.02.19	Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry (Businesswire)
10.12.18	Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten